

Recommendations from York and Scarborough Medicines Commissioning Committee July 2016

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Vancomycin	Treatment of C. difficile infection	Approved	To be recommended by consultant microbiologist only	As per local treatment guidelines	Amber SR (cons microbiologist)	None as currently commissioned
Caphosal (device)	Adjunct to radiotherapy for the management of radiation induced mucositis	Approved	To be provided by acute trust as part of radiotherapy treatment regime if required	As per radiotherapy guidance	Red – tertiary centre only	None in primary care – in tariff treatment
Orlistat	Obesity	Approved	Confirmation of formulary position	In line with NICE guidance	Green	None – formulary update not change
Omissions from Recommendations from December 2015 MCC						
Sastravi® (multiple strengths) Combination of carbidopa/levodopa/entacapone)	Parkinson's disease as per product license.	Approved	Offers better value than the reference product Stalevo®	Offer people with later stage Parkinson's disease taking entacapone, a triple combination preparation of levodopa, carbidopa and entacapone (NICE guidance)	Green	Cost savings represent £35.25 per 100 tablets
Stanek® (multiple strengths) Combination of	Parkinson's disease as	Approved	Offers better value than the reference product	Offer people with later stage Parkinson's	Green	Cost savings

carbidopa/levodopa/entacapone	per product license.		Stalevo®	disease taking entacapone, a triple combination preparation of levodopa, carbidopa and entacapone (NICE guidance)		represent £35.25 per 100 tablets
-------------------------------	----------------------	--	----------	---	--	----------------------------------